The first-in-class anti-CD47 product, Hu5F9, or 5F9, being developed by Stanford University spinout Forty Seven, is being tested as a treatment for patients with relapsed and/or refractory diffuse large B-cell lymphoma. "The most exciting part of this is that 5F9 is a novel form of immunotherapy that can induce durable remissions in lymphoma patients who were refractory to previous therapy," said first author Dr. Mark Roschewski during a presentation of data at the 24th Congress of the European Hematology Association.
New drug benefits relapsed/refractory DLBCL patients, study finds
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.